| Molecular Weight: | 410.39 |
| Formula: | C18H21F3N6O2 |
| Purity: | ≥98% |
| CAS#: | 944396-07-0 |
| Solubility: | DMSO up to 100 mM |
| Chemical Name: | 5-(2,6-dimorpholinopyrimidin-4-yl)-4-(trifluoromethyl)pyridin-2-amine |
| Storage: | Powder:4oC 1 year. DMSO:4oC3 month;-20oC 1 year. |
Biological Activity:BKM120 (NVP-BKM120) is a potent and selective, orally available pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor. It inhibits all four class-I PI3K isoforms in biochemical assays with IC50 ~50-250 nM, but exhibits selectivity of >100 folds against other protein kinases. It is also active against the most common somatic PI3Ka mutations but does not significantly inhibit the related class-III (Vps34) and class-IV (mTOR, DNA-PK) PI3K kinases. BKM120 has shown to significantly inhibit cell growth and induce apoptosis in a variety of tumor cell lines as well as in animal models. Consistent with its mechanism of action, NVP-BKM120 decreases the cellular levels of p-Akt in relevant models, as well as modulates downstream effectors in a concentration dependent and pathway-specific manner.
How to Use:
- In vitro: BKM120 was typically used at 1 µM in vitro and cellular assays.
- In vivo: BKM120 was formulated in NMP/PEG300 (10/90, v/v) and orally dosed to mice at 10 mg/kg once per day.
Reference:
- 1. Maira SM, et al. Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. (2012) Mol Cancer Ther. 11(2):317-28.
- 2. Koul D, et al. Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells. (2012) Clin Cancer Res. 18(1):184-95.
- 3. Park E, et al. NVP-BKM120, a novel PI3K inhibitor, shows synergism with a STAT3 inhibitor in human gastric cancer cells harboring KRAS mutations. (2012) Int J Oncol. 40(4):1259-66
- 4. Brachmann SM, et al. Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations. (2012) Mol Cancer Ther.
- 5.Ren H, et al. The combination of RAD001 and NVP-BKM120 synergistically inhibits the growth of lung cancer in vitro and in vivo.
BKM120_spec.pdf- BKM120_MSDS.pdf
Products are for research use only. Not for human use.
Xcess Biosciences，Inc.（XcessBio）由一群来自学术界和制药/生物技术行业的顶尖科学家于2008年成立，他们在药物化学，生物化学，分子和细胞生物学领域拥有丰富的专业知识。结合我们的合作者和顾问网络，我们致力于开发高质量的产品并提供最佳的服务，以满足生物医学研究中未满足的需求。
XcessBio的总部位于加利福尼亚州圣地亚哥，在最先进的研发设施中运营，设有化学合成实验室，分子和细胞生物学实验室以及分析质量控制实验室。
XcessBio一直为美国许多顶级制药，生物技术和试剂公司提供CRO服务和OEM产品，现在，我们将最好的产品和服务直接扩展到整个生命科学界。
暂无问答
本网站将在规定时间内给予删除等相关处理。
